Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;35(5):502-509.
doi: 10.5114/ada.2018.77242. Epub 2018 Jul 19.

Variances in the mRNA expression profile of TGF-β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patients

Anna Michalska-Bańkowska  1 , Dominika Wcisło-Dziadecka  2 , Beniamin Grabarek  3 , Ligia Brzezińska-Wcisło  1 , Urszula Mazurek  3 , Natalia Salwowska  1 , Mirosław Bańkowski  4
Affiliations

Variances in the mRNA expression profile of TGF-β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patients

Anna Michalska-Bańkowska et al. Postepy Dermatol Alergol. 2018 Oct.

Abstract

Introduction: Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disease, strongly associated with a higher level of a number of cytokines, such as isoforms of transforming growth factor β (TGF-β1-3) and its receptors (TGF-βRI-III). One of the most popular and important drugs used to treat this disease is cyclosporin A (CsA).

Aim: The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of TGF-β1-3 and its receptors TGF-βRI-III as the supplementary molecular markers of lost sensitivity to the medicine.

Material and methods: The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of TGF-β1-3 and TGF-βRI-III were performed by real-time quantitative reverse transcription PCR (RTqPCR).

Results: The expression of TGF-β1-3 and TGF-βRI-III were detected in the whole period of therapy with CsA. Changes in transcriptional activities of TGF-β1-3 and TGF-βRI-III during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.

Conclusions: The changes in expression profiles of TGF-β1-3 and TGF-βRI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.

Keywords: cyclosporin A; mRNA; psoriasis; transforming growth factor β1–3.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TGF-β1–3 expression profile on the day of therapy commencement day 0 (A), on day 42 (B), on day 84 (C)
Figure 2
Figure 2
TGF-βRI-III expression profile on the day of therapy commencement day 0 (A), on day 42 (B), on day 84 (C)
See this image and copyright information in PMC

References

    1. Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;24:15382. - PMC - PubMed
    1. Wang H, Peters T, Sindrilaru A, et al. TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest. 2008;118:2629–39. - PMC - PubMed
    1. Szepietowski J, Adamski Z, Chodorowska G, et al. Leczenie łuszczycy – rekomendacje ekspertów Polskiego Towarzystwa Dermatologicznego. Część II: łuszczyca umiarkowana do ciężkiej. Przegl Dermatol. 2014;101:455–72.
    1. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–24. - PubMed
    1. Praveenkumar U, Ganguly S, Ray L, et al. Prevalence of metabolic syndrome in psoriasis patients and its relation to disease duration: a hospital based case-control study. J Clin Diagn Res. 2016;10:WC01–5. - PMC - PubMed